Liminatus Pharma faces potential Nasdaq delisting after failing $1 minimum bid price rule

LIMN•2026-07-24

Reverse stock split vote scheduled for Aug. 3

A reverse stock split vote is scheduled for Aug. 3, 2026, following a definitive proxy filing on July 13, 2026.

Nasdaq deficiency notice and hearing panel review

Nasdaq notified Liminatus Pharma on July 20, 2026 that it remains below the $1 minimum bid price requirement under Listing Rule 5450(a)(1).

Nasdaq said the company is not eligible for a second 180-day compliance extension, and the Nasdaq Hearings Panel will weigh the deficiency. The panel has not issued a continued-listing decision; a written response is due by July 27, 2026.

Sources

Liminatus Pharma faces potential Nasdaq delisting after failing $1 minimum bid price rule

Sec

Liminatus Pharma faces potential Nasdaq delisting after failing $1 minimum bid price rule

Reverse stock split vote scheduled for Aug. 3

Nasdaq deficiency notice and hearing panel review

Related News

Embraer's backlog hit record $34.5 billion in the second quarter

BMO Asset Management plans 10-for-1 unit splits for ZGD and ZJG gold ETFs

Trump says he won't proceed with nuclear deal unless Saudis join Abraham Accords

Sources

Liminatus Pharma faces potential Nasdaq delisting after failing $1 minimum bid price rule

Surf Air Mobility Receives Continued Listing Standard Notice From NYSE

Mink Brook Asset Management reports DLH Holdings common share purchase valued at $2,394